HDAC9 and Hodgkins lymphoma: Based upon preclinical data showing synergy with combined mTOR and HDAC targeting, a Phase 1 trial in both relapsed non-Hodgkin lymphoma (NHL) and HL of everolimus and the HDAC inhibitor panobinostat was performed and resulted in a similar 43% response rate in patients with HL.